Cerus (NASDAQ:CERS) Announces Earnings Results

Cerus (NASDAQ:CERS) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.01), Zacks reports. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%.

Cerus Stock Down 3.9 %

CERS stock traded down $0.07 during midday trading on Thursday, hitting $1.74. The company’s stock had a trading volume of 1,189,219 shares, compared to its average volume of 1,460,745. The company’s fifty day moving average price is $1.74 and its 200 day moving average price is $1.84. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus has a twelve month low of $1.38 and a twelve month high of $2.59. The stock has a market capitalization of $323.14 million, a P/E ratio of -15.82 and a beta of 1.29.

Insider Transactions at Cerus

In related news, Director Eric Bjerkholt sold 20,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the completion of the transaction, the director now directly owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This represents a 10.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.40% of the company’s stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.